Alpha Tau to Participate in May Investor Conferences
01 Mayo 2024 - 7:30AM
Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:
DRTS, DRTSW), the developer of the innovative alpha-radiation
cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy
will present at the following investor conferences in May 2024.
Event: |
Guggenheim Securities Radiopharmaceuticals Day |
Format: |
Presentation |
Date: |
May 13, 2024 |
Time: |
11:30AM ET |
Location: |
New York, NY |
Event: |
H.C. Wainwright 2ndAnnual BioConnect Investor Conference |
Format: |
Fireside Chat |
Date: |
May 20, 2024 |
Time: |
2PM ET |
Location: |
New York, NY |
Mr. Levy will also be available for 1x1 investor meetings at the
conferences. Please reach out to your Guggenheim Securities and
H.C. Wainwright representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company
that focuses on research, development, and potential
commercialization of the Alpha DaRT for the treatment of solid
tumors. The technology was initially developed by Prof. Itzhak
Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is
designed to enable highly potent and conformal alpha-irradiation of
solid tumors by intratumoral delivery of radium-224 impregnated
sources. When the radium decays, its short-lived daughters are
released from the sources and disperse while emitting high-energy
alpha particles with the goal of destroying the tumor. Since the
alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims
to mainly affect the tumor, and to spare the healthy tissue around
it.
Investor Relations Contact:
IR@alphatau.com
Alpha Tau Medical (NASDAQ:DRTS)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Alpha Tau Medical (NASDAQ:DRTS)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024